|Biochemicals||Storage: -20°CShipping: Blue Ice|
A farnesyltransferase inhibitor. Sensitizes human multiple myeloma cell to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. Also shown to inhibit the growth of myeloid leukemia cell lines and primary leukemia cells by inducing apoptosis and cell-cycle blockage when combined with rapamycin(R124000).
+20.9°C (c=0.7, Methanol)
Method for Determining Identity:
Proton NMR, (CDCI3) Spectroscopic and Mass Spectrometric Analysis
SiO2; Dichloromethane: Methanol=9:1; Visualized with UV and AMCS; Single spot. Rf=0.45.
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Toxicity and Hazards:
All products should be handled by qualified personnel only, trained in laboratory procedures.
Form: Supplied as an off-white to pale beige solid.
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
David, E., et al.: Blood, 116, 5285 (2010); Nagai, T., et al.: Leukemia Res., 34, 1057 (2010); Hong, D., et al.: Clin. Cancer Res., 15, 7061 (2009)